Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.

Cancer Med · 2023 · PMC9972105 · PMID 36151699

Europe PMC DOI

hedged sentences

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

of marginal significancep < 0.15not close (p > 0.1)

Variables with associations of marginal significance (two‐sided p < 0.15) were further used to build the multivariate model.

also in 464 other papers

marginally significantno p-value reported

Other factors showed no significant or marginally significant associations. 3.8.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.